For a pathologist, the foundational act of diagnosis is a compromise. A tissue biopsy is a three-dimensional object, but the standard of care involves slicing it into thin, two-dimensional sections. The process is destructive, and it can miss critical biological context that exists in the volume of the sample. Alpenglow Biosciences, a Seattle-based biotech spun out of the University of Washington, is building a clinical argument that this compromise is no longer necessary. Its platform images entire, intact tissue samples in three dimensions, then uses AI to convert those volumetric maps into quantitative readouts for drug developers and, increasingly, for diagnosing patients.
Its bet is that this 3D spatial biology approach will reveal biomarkers and morphological details invisible to conventional pathology, offering a more complete picture for both research and clinical decision-making. The company's progress is being measured not just in venture rounds, but in the kind of validation that matters in medicine: substantial, non-dilutive contracts from the agencies that fund high-risk, high-reward biomedical technology.
The Wedge: From Open-Top Microscopy to Clinical AI
Alpenglow's technical foundation is a patented open-top light-sheet microscope. Unlike conventional microscopes that require samples to be mounted on slides, this design allows intact tissue specimens to be placed in an open chamber and imaged from the side with a thin sheet of light. The result is high-resolution 3D data without physical sectioning. This hardware wedge is paired with a growing software layer, Summit AI, which analyzes the volumetric datasets to identify and quantify cellular structures and spatial relationships.
The platform's applications span from early drug discovery,helping pharmaceutical companies understand a drug's mechanism of action or toxicity in three dimensions,to its more ambitious goal: clinical diagnostics. The company is pursuing this through specific, funded pathways. A $2 million Phase II SBIR contract from the National Institutes of Health (NIH) is supporting work with CorePlus, a digital pathology lab, to develop AI-enabled diagnostics for prostate cancer [GeekWire, August 2024]. Separately, scientific co-founder Jonathan Liu is the principal investigator on an up to $21 million, five-year contract from ARPA-H to develop a platform for precision tumor removal [GeekWire, August 2024].
Validation Through Non-Dilutive Capital
While Alpenglow has raised approximately $11.25 million in investor funding since 2018, led consistently by Dynamk Capital, its government contract portfolio now overshadows that figure. Combined ARPA-H and NIH awards exceed $24 million, a signal that its technology is being evaluated for mission-critical problems in oncology [Business Wire, August 2024]. This funding mix is telling. Grant and contract awards from agencies like NIH and ARPA-H are competitive and peer-reviewed, suggesting a level of technical credibility that has attracted strategic partnerships with Mayo Clinic and an instrumentation giant, ZEISS [Alpenglow Biosciences, retrieved 2026] [ZEISS, retrieved 2026].
Seed Investor Funding (2021-2026) | 11.25 | M USD
Government Contracts (ARPA-H & NIH) | 24 | M USD
The Path to the Clinic
The company's strategy for clinical adoption involves embedding its technology within established diagnostic workflows. A partnership with PathNet, a U.S. pathology laboratory network, aims to commercialize the 3D microscope in clinical settings [GeekWire, January 2026]. Another deal with Virdx focuses on advancing AI-enabled prostate cancer diagnostics [Business Wire, October 2025]. These moves indicate a focus on urologic oncology as an initial beachhead, leveraging the high volume and clinical need in prostate cancer diagnosis.
Internally, Alpenglow is working to make its complex technology more accessible. In March 2025, it launched LUMI, an interface designed to simplify the microscopy workflow with real-time previews, a nod to the usability required for broader adoption beyond expert labs [Business Wire, March 2025].
The Team and the Traction
The company's origins are deeply academic, with founding team members holding affiliations at the University of Washington and the Allen Institute. CEO Nicholas Reder is a board-certified pathologist, and the original concept emerged from his residency work, grounding the company's vision in clinical reality [Perplexity Sonar Pro Brief, retrieved 2024]. The advisory board has been bolstered by industry veterans like Mike Rice, former CEO of BioLife Solutions, who also became an investor [Alpenglow Biosciences, retrieved 2026] [GeekWire, January 2026].
Traction appears across three vectors: grant funding, strategic partnerships, and early commercial activity. The company lists biopharma clients like GSK and Incyte for its research services, and its employee count has grown from three in 2021 to an estimated 22 as of early 2026 [GeekWire, January 2026] [Alpenglow Biosciences, 2023].
| Founder / Key Leader | Role | Relevant Background |
|---|---|---|
| Nicholas Reder, MD, MPH | CEO, Co-Founder | Board-certified pathologist; concept originated from UW pathology residency. |
| Jonathan T.C. Liu, PhD | Scientific Co-Founder | UW professor; PI on ARPA-H contract. |
| Adam Glaser | Co-Founder | Senior scientist at Allen Institute. |
| Lawrence True | Co-Founder | UW-affiliated pathology researcher. |
| Mike Rice | Advisor & Investor | Former Chairman/CEO of BioLife Solutions. |
Navigating a Crowded Diagnostic Landscape
The primary competitive risk for Alpenglow is not a lack of innovation, but the immense inertia of the global pathology system. The company is asking clinicians and labs to adopt a new, complex hardware and software workflow that departs from a century-old standard. Its most direct competitor in spatial biology is Akoya Biosciences, which has a significant commercial footprint with its multiplexed immunohistochemistry platforms. Akoya's approach, however, largely remains within the paradigm of 2D tissue sections.
Alpenglow's answer to this challenge is multifaceted, built on the specific advantages its technology claims.
- Regulatory and clinical partnerships. By working directly with entities like Mayo Clinic and PathNet, and pursuing diagnostics through NIH-funded clinical studies, the company is building the evidence base required for adoption [Alpenglow Biosciences, retrieved 2026].
- Strategic hardware collaboration. The partnership with ZEISS to develop an inverted light-sheet microscope for clinical applications provides credibility and could ease future manufacturing and distribution [ZEISS, retrieved 2026].
- Focus on high-value decisions. Targeting areas like prostate cancer grading and tumor margin assessment,where 3D context could directly alter surgical or treatment plans,aims to demonstrate clear clinical utility over the incumbent standard.
The next twelve months will be critical for translating contract wins into tangible clinical milestones. Key metrics to watch will be the publication of validation data from the NIH prostate cancer work, any regulatory (FDA) submissions for its AI algorithms, and the scaling of its PathNet partnership into routine clinical use.
For patients facing a prostate cancer diagnosis, the current standard of care involves a pathologist examining thin slices of biopsy tissue under a microscope, assigning a Gleason score based on the two most prevalent patterns of cancer cells. It's a powerful, but inherently limited, 2D snapshot of a 3D disease. Alpenglow's ambition is to replace that snapshot with a volumetric map, arguing that a fuller picture will lead to more precise grading and better-informed treatment decisions. The company's growing stack of government contracts suggests that funders, at least, believe the argument is worth a very expensive test.
Sources
- [GeekWire, August 2024] Alpenglow Biosciences lands new contracts to develop 3D pathology tech | https://www.geekwire.com/2024/alpenglow-biosciences-lands-new-contracts-to-develop-3d-pathology-tech/
- [GeekWire, January 2026] Seattle’s Alpenglow moves 3D microscope tech from lab to clinic to help modernize cancer diagnostics | https://www.geekwire.com/2026/seattles-alpenglow-moves-3d-microscope-tech-from-lab-to-clinic-to-help-modernize-cancer-diagnostics/
- [Business Wire, August 2024] Alpenglow Biosciences and Partners Secure a Total of $24M for Development of Alpenglow’s 3D Spatial Pathology Platform | https://www.businesswire.com/news/home/20240815473451/en/Alpenglow-Biosciences-and-Partners-Secure-a-Total-of-%2424M-for-Development-of-Alpenglows-3D-Spatial-Pathology-Platform
- [Business Wire, March 2025] Alpenglow Biosciences Unveils New Imaging Interface for Light-Sheet Microscopy | https://www.businesswire.com/news/home/20250320005142/en/Alpenglow-Biosciences-Unveils-New-Imaging-Interface-for-Light-Sheet-Microscopy
- [Business Wire, October 2025] Alpenglow Biosciences and Virdx Announce Strategic Deal to Advance AI-Enabled Prostate Cancer Diagnostics | https://www.businesswire.com/news/home/20251007193794/en/Alpenglow-Biosciences-and-Virdx-Announce-Strategic-Deal-to-Advance-AI-Enabled-Prostate-Cancer-Diagnostics
- [Alpenglow Biosciences, retrieved 2026] Alpenglow Biosciences and PathNet Form Strategic Partnership | http://alpenglowbiosciences.com/press-releases/alpenglow-pathnet-partnership
- [ZEISS, retrieved 2026] ZEISS Partners with Alpenglow Biosciences | https://www.zeiss.com/microscopy/en/news-and-events/newsroom/press-releases/2026/zeiss-partners-with-alpenglow-biosciences.html
- [Perplexity Sonar Pro Brief, retrieved 2024] Alpenglow Biosciences Company Brief
- [Alpenglow Biosciences, 2023] Company history and 2021 funding announcement | https://www.alpenglowbiosciences.com/news/lightspeed-microscopy-inc-rebrands-as-alpenglow-biosciences